Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W.
Chortis V, et al. Among authors: hughes ba.
J Clin Endocrinol Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16.
J Clin Endocrinol Metab. 2013.
PMID: 23162091
Free article.
Clinical Trial.